Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1904 - The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Colorectal Cancer

Date

09 Sep 2017

Session

Poster display session

Topics

Translational Research;  Colon and Rectal Cancer

Presenters

Satoshi Yuki

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

S. Yuki1, T. Kato2, H. Taniguchi3, T. Hamaguchi4, K. Akagi5, T. Denda6, T. Mizukami7, E. Oki8, T. Yamada9, M. Shiozawa10, T. Kudo11, T. Tamura12, T. Esaki13, D. Naruge14, T. Kajiwara15, S. Nomura16, S. Fujii17, K. Shitara18, A. Ohtsu18, T. Yoshino18

Author affiliations

  • 1 Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 2 Gastrointestinal Surgery, Kansai Rosai Hospital, 660-8511 - Amagasaki/JP
  • 3 Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 4 Gastrointestinal Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 5 Molecular Diagnosis And Cancer Prevention, Saitama Cancer Center, Saitama/JP
  • 6 Gastroenterology, Chiba Cancer Center, 260-8717 - Chiba/JP
  • 7 Clinical Oncology, St.Marianna University School of Medicine, 216-8511 - Kanagawa/JP
  • 8 Surgery And Science, Graduate School Of Medical Sciences, Kyushu University, 812-8582 - Fukuoka/JP
  • 9 Gastroenterology, University of Tsukuba, Faculty of Medicine, Tsukuba/JP
  • 10 Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa/JP
  • 11 Frontier Science For Cancer And Chemotherapy, Osaka University Graduate School of Medicine, 565-0871 - Suita/JP
  • 12 Medical Oncology, Kindai University Faculty of Medicine, Osaka/JP
  • 13 Gastrointestinal And Medical Oncology, National Kyushu Cancer Center, Fukuoka/JP
  • 14 Medical Oncology, Kyorin University Faculty of Medicine, 181-8611 - Mitaka, Tokyo/JP
  • 15 Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama/JP
  • 16 Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa/JP
  • 17 Pathology Division, Research Center For Innovative Oncology, National Cancer Center, 277-8577 - Kashiwa/JP
  • 18 Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
More

Resources

Abstract 1904

Background

We initiated the Nationwide Cancer Genome Screening Project in Japan since February 2014. From February 2015, we have introduced the Next Generation Sequencing to detect cancer genome alterations in advanced colorectal cancer (aCRC), called as the SCRUM-Japan GI-SCREEN. The objective is to evaluate the frequency of cancer genome alterations and to identify patients who are candidate for clinical trial with corresponding targeting agents.

Methods

This study is ongoing with 20 major cancer centers. Patients with aCRC who plan to or receive chemotherapy were eligible. DNA and RNA were extracted from formalin-fixed paraffin embedded (FFPE) tumor samples and were analyzed by the Oncomine Cancer Research Panel (OCP) which allows to detect mutations, copy number variant (CNV) and fusion genes in a CLIA certified CAP accredited lab. The detected genomic variant data were classified according to genetic drivers of cancer, including gain- and loss-of-function or single nucleotide variant based on the Oncomine Knowledgebase.

Results

As of October 31st in 2016, total of 1011 aCRC patients were enrolled and 981 samples were analyzed. The sequence was successfully performed in 751 tumors (76.6%). Out of 751 patients, the origin of samples included the primary site of 83.1% (Right-side 24.6%, Left-side 58.5%), metastatic site of 15.3%, and unknown of 1.6%. The frequently detected mutations in 751 samples of which results were available were TP53 (69.0%), APC (62.8%), and KRAS (43.8%), and CNVs (≥ 7copies) were FLT3 (3.6%), ERBB2 (2.8%), and MYC (2.7%). BRAF V600E was identified in 48 cases (6.4%) and CCDC6-RET fusion was identified in one case (0.1%). We will show the clinical outcome based on certain key cancer genome alterations.

Conclusions

This nationwide screening system is efficient to detect rare gene alterations in aCRC. This novel knowledge provides an intriguing background to investigate new targeted approaches in these patients and represents the progress toward precision medicine.

Clinical trial identification

UMIN000016343, 2015/01/26

Legal entity responsible for the study

SCRUM-Japan GI-SCREEN

Funding

15 SCRUM-Japan collaborating pharmaceutical companies, AMED, NCC

Disclosure

S. Yuki: Honoraria: Taiho Pharmaceutical, Takeda Pharmaceutical, Merck Serono, Eli Lilly Japan, Chugai Pharmaceutical, Bayer Yakuhin, Bristol-Myers Squibb. T. Kato: Speakers’ Bureau: Takeda Pharmaceutical, Eli Lilly Japan, Chugai Pharmaceutical, Yakult Honsha. H. Taniguchi: Honoraria: Taiho Pharmaceutical, Takeda Pharmaceutical, Merck Serono, Eli Lilly Japan, Chugai Pharmaceutical, Bayer Yakuhin, Yakult Honsha. Research funding: Takeda Pharmaceutical, Otsuka Pharmaceutical, Boehringer Ingelheim Japan, MSD. T. Hamaguchi: Honoraria: Chugai, Merck Serono, Takeda, Yakult Honsha, Taiho. Advisory Role: NanoCarrier. Research funds: Dainippon Sumitomo, Sanofi, NanoCarrier, MSD, Taiho, Ono, Daiichi Sankyo, Teijin. E. Oki: Speakers’ Bureau: Taiho Pharmaceutical, Yakult Honsha, Chugai Pharmaceutical, Eli Lilly Japan, Bayer Yakuhin, Merck Serono, Takeda Pharmaceutical. T. Yamada: Speakers’ Bureau: Chugai Pharmaceutical. T. Kudo: Research funding: Yakult Honsha, Chugai Pharmaceutical, Ono Pharmaceutical. T. Esaki: Honoraria and/or research funding: Chugai Pharmaceutical, Eli Lilly Japan, Taiho Pharmaceutical, Merck Serono, Ono Pharmaceutical, Nihon Kayaku, Eisai, Novartis, Daiichi-Sankyo, DS Pharma, AstraZeneca, Boehringer-Ingelheim Japan, MSD. D. Naruge: Taiho, Ono, Onco Therapy Science, Merck Serono, Eli Lilly Japan, Takeda, Chugai, Bayer, Graxo Smith Kline, Yakult, Sumitomo Dainippom, Daiichi Sankyo, Shionogi, Novartis, Nippon Kayaku, BMS, Sanofi, Kyowa Hakko Kirin, Astellas, Hisamitsu, Pfizer. S. Nomura: Employment Asahi-Kasei Pharmaceutical. K. Shitara: Receipt of grants/research supports: Daiichi Sankyo, Chugai Pharma, Lilly, MSD, Taiho Pharmaceutical, Dainippon Sumitomo Pharma. A. Ohtsu: Employment (an immediate family member): Celgene. Research funding: BMS. T. Yoshino: Research funding: GlaxoSmithKline K. K, Boehringer-Ingelheim GmbH. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.